CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
病毒特异性 T 细胞疗法在 BMT 后的应用
英文原题：Applications of virus-specific T cell therapies post-BMT.
查看英文原题
Applications of virus-specific T cell therapies post-BMT.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
造血干细胞移植（HSCT）作为中重度原发性免疫缺陷病以及复发性血液系统恶性肿瘤的治愈性标准治疗手段，已应用超过50年[1,2]。然而，慢性和难治性病毒感染仍是HSCT后免疫缺陷期发病和死亡的主要原因，现有抗病毒药物的使用受到毒性和新发耐药性的限制[3]。使用病毒特异性T细胞（VSTs）的过继免疫治疗已在HSCT后患者中探索了20余年[4,5]，此前的I-II期研究已表明，该疗法在治疗或预防包括巨细胞病毒、EB病毒、BK病毒和腺病毒在内的病毒感染方面安全有效，且毒性极小、移植物抗宿主病风险低[6-9]。本综述总结了生成VSTs的方法学、利用VST治疗药物的临床结果以及该领域面临的挑战和未来方向。
展开英文摘要原文
Hematopoietic stem cell transplantation (HSCT) has been used as a curative standard of care for moderate to severe primary immunodeficiency disorders as well as relapsed hematologic malignancies for over 50 years [1,2].
However, chronic and refractory viral infections remain a leading cause of morbidity and mortality in the immune deficient period following HSCT, where use of available antiviral pharmacotherapies is limited by toxicity and emerging resistance [3].
Adoptive immunotherapy using virus-specific T cells (VSTs) has been explored for over 2 decades [4,5] in patients post-HSCT and has been shown prior phase I-II studies to be safe and effective for treatment or preventions of viral infections including cytomegalovirus, Epstein-Barr virus, BK virus, and adenovirus with minimal toxicity and low risk of graft vs host disease [6-9]. This review summarizes methodologies to generate VSTs the clinical results utilizing VST therapeutics and the challenges and future directions for the field.
论文信息
- 作者
- Motta CM、Keller MD、Bollard CM
- 单位
- Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC. Electronic address: cmotta@childrensnational.org.United States
- 文献类型
- 综述
- 期刊
- Seminars in hematology2023 Jan
- 原文标识
- PubMed 37080705 · DOI 10.1053/j.seminhematol.2022.12.002